search
Back to results

Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia

Primary Purpose

Critical Limb Ischemia, Peripheral Arterial Disease, Buerger's Disease

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
ResQ processed bone marrow sample
Ficoll conventional cell processing method
Sponsored by
Xuanwu Hospital, Beijing
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Limb Ischemia focused on measuring Peripheral arterial disease, Buerger's disease, atherosclerotic arterial occlusion, bone marrow mononuclear cell, chronic limb ischemia

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. fontaine's stage 2-4 or resting ABI <0.7
  2. age between 20 and 80 years old
  3. sign informed consent, voluntary subjects
  4. diagnosis of lower extremity arterial occlusive disease, or diabetic lower limb ischemia, or Buerger's disease

Exclusion Criteria:

  1. poorly controlled diabetes (HBA1c> 7.0%) and proliferative retinopathy (III-IV stage)
  2. malignancy history in the past five years or serum level of tumor markers elevated more than doubled
  3. severe heart, liver, kidney, respiratory failure or poor general condition can not tolerate BM-MNC transplantation
  4. serious infections (such as cellulitis, osteomyelitis, etc.)or gangrene that a major amputation cannot be avoided
  5. aortic or iliac or common femoral artery occlusion
  6. pregnant female, or reproductive age female who wants to give birth throughout the course of the study
  7. life expectancy less than a year

Sites / Locations

  • Xuan Wu Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ResQ process group

Ficoll-based conventional method

Arm Description

Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.

A conventional method based on Ficoll cell separation is used to process bone marrow.

Outcomes

Primary Outcome Measures

Cell treatment-related adverse event
Temperature,Pulse,Respiration,Blood Pressure Routine analysis of blood and urine, Liver function(ALT:alanine aminotransferase,AST:aspartate transferase), Renal function(Blood urea nitrogen,Creatinine;) Function of coagulation(APTT,PT,Fib,TT) ECG(Electrocardiography) local inflammatory response Cell-treatment related death Cell-treatment related unexpected amputation.

Secondary Outcome Measures

ulcer size
Measuring ulcer area (cm2) and depth (mm)of limb : For each ulcer , photographically record the area and depth with a ruler in order to calculate the ulcer area in square millimeters.
rest pain score.
Scoring the rest pain based on the degree of pain as following five scales): 0 level-0 point: no pain; level-1 point: occasional pain which can be recalled; level-2 points: the pain often but can be tolerated, without or with a little analgesics; level-3 points: often with need of general analgesics; level -4 points: affect sleeping due to the pain, general pain medication being difficult to alleviate. Before transplantation: points; after transplantation: points.
cold sensation score
based on a sense of cold as following five scales: 0 level-0 point: no cold sensation; level-1 point, or : Accasionally cold feeling; level-2 points: Often with cold feeling; level-3 points: significantly cold feeling. and can be significantly improved when using a local insulation. level-4 points: significantly cold feeling,and can not be significantly improved when using a local insulation.
claudication distance (m)
Measurement of claudication distance (m): For patients with intermittent claudication, treadmill exercise test (no tilt, speed 3km/hr) is employed to measure claudication distance.
Resting ABI
Measurement of ABI(ankle brachial index, ABI): Measure arterial pressure with a laser Doppler, and then calculate the ankle-brachial index, that is a ratio of ankle arterial blood pressure to brachial arterial blood pressure at rest.
Resting TcPO2 (mmHg)
Transcutaneous oxygen pressure(TcPO2) should be measured at the same site in the ischemic limb at rest.
Collateral vessel score
Collateral vessel score: Using DSA(Digital subtraction angiography)or CTA(computed tomographic angiography) to score the collateral vessel formation. A mean score is obtained for each ischemic limb by 3 independent interventionists based on the following 4 level score: 0 (no new collateral vessels) 1 (A little new collateral vessels) 2 (moderate new collateral blood vessels) 3 (Rich new collateral vessels)
Amputation rate
Amputation rate and level is recorded.
Skin microcirculation measurement
using PeriMed "laser-Doppler flowmetry" measure the skin microcirculation on the same site in the ischemic limb at rest.
Resting TBI
Measurement of TBI(Toe Brachial Index): Measure arterial pressure with a laser Doppler, and then calculate Toe Brachial Index, that is a ratio of toe arterial blood pressure to brachial arterial blood pressure.

Full Information

First Posted
September 23, 2011
Last Updated
October 8, 2011
Sponsor
Xuanwu Hospital, Beijing
Collaborators
Thermogenesis Corp., Hebei Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT01446055
Brief Title
Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia
Official Title
Transplantation of Autologous BM-MNC Processed by ResQ Separator and Conventional Manual Method for Patients With Chronic Limb Ischemia: a Multi-center Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2011
Overall Recruitment Status
Unknown status
Study Start Date
October 2011 (undefined)
Primary Completion Date
April 2012 (Anticipated)
Study Completion Date
April 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Xuanwu Hospital, Beijing
Collaborators
Thermogenesis Corp., Hebei Medical University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Using autologous bone marrow mononuclear cells (BM-MNC) to treat patients with chronic limb ischemia has been proved safe and effective. However, processing bone marrow by Ficoll density gradient centrifugation is not only time consuming but also expensive. Manually processing of bone marrow also results in large variation in therapeutic cell quantity and quality which directly leads deviation of safety and efficacy of the cell therapy. This study is aiming to compare an automated bone marrow processing system with a conventional manual method in term of safety and efficacy.
Detailed Description
Using autologous bone marrow mononuclear cells (BM-MNC) to treat patients with chronic limb ischemia has been proved safe and effective. However, processing bone marrow by Ficoll density gradient centrifugation is not only time consuming but also expensive. Manually processing of bone marrow also results in large variation in therapeutic cell quantity and quality which directly lead deviation of safety and efficacy of the cell therapy. This study is aiming to compare an automated bone marrow processing system with a conventional manual method in term of safety and efficacy. ResQ system developed by Thermogenesis in USA provides an automatic cell processing system for bone marrow. The system takes less than 30 minutes to concentrate the therapeutic mononuclear cells including stem cells in a closed system without adding any additive such as separation reagent (Ficoll). The system also be able to be operated at point of care. The study is designed to prove no inferior of safety and efficacy of bone marrow cells processed by ResQ to those of cells using conventional manual method. The conventional manual method is involved Ficoll density gradient centrifugation and cell washing stems in an open system. Each of test arms (ResQ vs manual method) consists of 25 patients. The primary outcome is safety which is measured by cell treatment-related adverse events. The secondary endpoints include resting ankle-brachial pressure index (ABI)and toe brachial pressure index (TBI) , transcutaneous oxygen pressure (TcPO2), claudication distance, rest pain scale evaluation, collateral vessel scale, etc.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Limb Ischemia, Peripheral Arterial Disease, Buerger's Disease
Keywords
Peripheral arterial disease, Buerger's disease, atherosclerotic arterial occlusion, bone marrow mononuclear cell, chronic limb ischemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ResQ process group
Arm Type
Experimental
Arm Description
Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
Arm Title
Ficoll-based conventional method
Arm Type
Active Comparator
Arm Description
A conventional method based on Ficoll cell separation is used to process bone marrow.
Intervention Type
Device
Intervention Name(s)
ResQ processed bone marrow sample
Intervention Description
Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
Intervention Type
Device
Intervention Name(s)
Ficoll conventional cell processing method
Intervention Description
Comparison of different cell processing methods
Primary Outcome Measure Information:
Title
Cell treatment-related adverse event
Description
Temperature,Pulse,Respiration,Blood Pressure Routine analysis of blood and urine, Liver function(ALT:alanine aminotransferase,AST:aspartate transferase), Renal function(Blood urea nitrogen,Creatinine;) Function of coagulation(APTT,PT,Fib,TT) ECG(Electrocardiography) local inflammatory response Cell-treatment related death Cell-treatment related unexpected amputation.
Time Frame
2-wk after bone marrow transplantation
Secondary Outcome Measure Information:
Title
ulcer size
Description
Measuring ulcer area (cm2) and depth (mm)of limb : For each ulcer , photographically record the area and depth with a ruler in order to calculate the ulcer area in square millimeters.
Time Frame
Post bone marrow transplantation: 1, 3, 6, 12 months
Title
rest pain score.
Description
Scoring the rest pain based on the degree of pain as following five scales): 0 level-0 point: no pain; level-1 point: occasional pain which can be recalled; level-2 points: the pain often but can be tolerated, without or with a little analgesics; level-3 points: often with need of general analgesics; level -4 points: affect sleeping due to the pain, general pain medication being difficult to alleviate. Before transplantation: points; after transplantation: points.
Time Frame
Post bone marrow transplantation: 1,3, 6, 12 months
Title
cold sensation score
Description
based on a sense of cold as following five scales: 0 level-0 point: no cold sensation; level-1 point, or : Accasionally cold feeling; level-2 points: Often with cold feeling; level-3 points: significantly cold feeling. and can be significantly improved when using a local insulation. level-4 points: significantly cold feeling,and can not be significantly improved when using a local insulation.
Time Frame
Post bone marrow transplantation:,1,3, 6, 12 months
Title
claudication distance (m)
Description
Measurement of claudication distance (m): For patients with intermittent claudication, treadmill exercise test (no tilt, speed 3km/hr) is employed to measure claudication distance.
Time Frame
Post bone marrow transplantation:1, 3, 6, 12 months
Title
Resting ABI
Description
Measurement of ABI(ankle brachial index, ABI): Measure arterial pressure with a laser Doppler, and then calculate the ankle-brachial index, that is a ratio of ankle arterial blood pressure to brachial arterial blood pressure at rest.
Time Frame
Post bone marrow transplantation: 1,3, 6, 12 months
Title
Resting TcPO2 (mmHg)
Description
Transcutaneous oxygen pressure(TcPO2) should be measured at the same site in the ischemic limb at rest.
Time Frame
Post bone marrow transplantation:1, 3, 6, 12 months
Title
Collateral vessel score
Description
Collateral vessel score: Using DSA(Digital subtraction angiography)or CTA(computed tomographic angiography) to score the collateral vessel formation. A mean score is obtained for each ischemic limb by 3 independent interventionists based on the following 4 level score: 0 (no new collateral vessels) 1 (A little new collateral vessels) 2 (moderate new collateral blood vessels) 3 (Rich new collateral vessels)
Time Frame
Post bone marrow transplantation: 1,3, 6, 12 months
Title
Amputation rate
Description
Amputation rate and level is recorded.
Time Frame
Post bone marrow transplantation:1, 3, 6, 12 months
Title
Skin microcirculation measurement
Description
using PeriMed "laser-Doppler flowmetry" measure the skin microcirculation on the same site in the ischemic limb at rest.
Time Frame
1,3,6,12 months post transplantation
Title
Resting TBI
Description
Measurement of TBI(Toe Brachial Index): Measure arterial pressure with a laser Doppler, and then calculate Toe Brachial Index, that is a ratio of toe arterial blood pressure to brachial arterial blood pressure.
Time Frame
Post bone marrow transplantation: 1,3, 6, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: fontaine's stage 2-4 or resting ABI <0.7 age between 20 and 80 years old sign informed consent, voluntary subjects diagnosis of lower extremity arterial occlusive disease, or diabetic lower limb ischemia, or Buerger's disease Exclusion Criteria: poorly controlled diabetes (HBA1c> 7.0%) and proliferative retinopathy (III-IV stage) malignancy history in the past five years or serum level of tumor markers elevated more than doubled severe heart, liver, kidney, respiratory failure or poor general condition can not tolerate BM-MNC transplantation serious infections (such as cellulitis, osteomyelitis, etc.)or gangrene that a major amputation cannot be avoided aortic or iliac or common femoral artery occlusion pregnant female, or reproductive age female who wants to give birth throughout the course of the study life expectancy less than a year
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yongquan Gu, MD
Phone
13910002909
Email
gu-yq@263.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong-Quan Gu, Dr.
Organizational Affiliation
Xuanwu Hospital, Beijing
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xuan Wu Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongquan Gu, MD
Phone
13910002909
Email
gu-yq@263.net
First Name & Middle Initial & Last Name & Degree
Yongquan Gu, MD

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia

We'll reach out to this number within 24 hrs